Moderna, Inc. , a biotechnology firm, is dedicated to the discovery, development, and commercialization of messenger RNA (mRNA) based therapies and preventive medicines.
Moderna stock last closed at $196.79, down 4.84% from the previous day, and has increased 689.69% in one year. It has overperformed other stocks in the Biotechnology industry by 7.85 percentage points. Moderna stock is currently +783.26% from its 52-week low of $22.28, and -29.92% from its 52-week high of $280.80.
There are currently 404.62M MRNA shares outstanding. The market value of MRNA is $79.63B. In the past 24 hours, 6.99M MRNA shares were traded.
How to Buy Moderna Stock
Not sure how to invest in Moderna stock? Here's how.
Decide where to buy Moderna stock: You need to pick an online brokerage, but don't worry - we've researched dozens of online stock brokerages and apps to help you determine where to buy Moderna stock.
Open a brokerage account: Sign up for 0% fee trading with the highest-rated brokerage we've selected.
Fund your investment account: Select your payment method and add your information.
Research Moderna stock: The Moderna ticker symbol is MRNA. Is Moderna stock a good investment? Should you buy shares of MRNA? How do MRNA's underlying business fundamentals look? Do top analysts think Moderna is a good buy? Why has MRNA's stock price moved recently? (Hint: Our stock market research website can help you figure out if MRNA is a good stock to buy).
Make your MRNA purchase: Decide if you will purchase MRNA shares at the current market price or use a limit order to buy MRNA shares at a given price.
Track your MRNA investment: Create a watchlist to keep track of your position in Moderna shares.
Step 1: Decide where to buy Moderna stock
You will need a brokerage account to access the NASDAQ market and buy MRNA stock.
A brokerage account allows you to buy and sell a variety of financial instruments, including stocks, bond ETFs, mutual funds, and ETFs.
Our preferred brokerage: eToro
Based on our analysis, eToro is the best stock brokerage. eToro gives you:
You can invest in stocks with zero commissions: Invest without commissions.
Buy fractional shares: Even if you don't have the money to buy a full share, you can still purchase the stock.
Access to global markets: From Technology to Financial Services, New York to Tokyo (for US users, only US stocks are available) — you can fill your portfolio with stocks from the globe's top exchanges.
Social investing: eToro boasts a community of more than 20 million users globally. Talk to, learn from, and copy the crypto trades of top investors.
Security: eToro is a regulated and licensed fintech leader.
Buy other assets: Such as ETFs and cryptocurrencies.
Get $10 towards your share purchase by creating an account with eToro today. This offer is only for US users.
eToro securities trading is offered by eToro USA Securities, Inc. (“the BD”), member of FINRA and SIPC. Cryptocurrency is offered by eToro USA LLC (“the MSB”) (NMLS: 1769299) and is not FDIC or SIPC insured. Investing involves risk, and content is provided for educational purposes only, does not imply a recommendation, and is not a guarantee of future performance. https://www.wallstreetzen.com is not an affiliate and may be compensated if you access certain products or services offered by the MSB and/or the BD.
Step 2: Open a brokerage account
Now that you've picked the best brokerage, the next step is to fill out some personal info so you can buy MRNA today.
eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
Step 4: Research Moderna stock
Once you have chosen the best place to buy Moderna stock, it's important to analyze their stock before you invest, so you actually comprehend the risk as well as the opportunity.
Moderna quick stats
MRNA Price
$196.79
1w %
-20.87%
1y %
689.69%
5y %
-21.73%
P/E
-27.8x
P/B
11.65x
P/S
31.25x
PEG
N/A
Revenue
$2.53B
Earnings
-$2.79B
Fore. Rev. Growth
12.47%
Fore. Earn. Growth
N/A
Market Cap
$79.63B
Next Earnings
N/A
Next Dividend
N/A
Moderna Fundamentals
WallStreetZen was built to help part-time investors do better fundamental analysis quickly.
There are more short-term assets than long-term liabilities on the MRNA balance sheet.
MRNA has cash burn of 2044000000. It has enough cash and short-term investments to cover this for at least one year.
Total MRNA debt is lower than 5 years ago, relative to shareholder equity.
MRNA has $5.17B in cash and short term investments. This is enough to cover its annual cash burn of $2.04B.
There are more short-term assets than short-term liabilities on the MRNA balance sheet.
Failed Financial Due Diligence Checks:
MRNA profit margin has gone up by 0.29 percentage points in the past year, but the company is still unprofitable.
MRNA has a relatively high debt to equity ratio of 0.97.
Is it a good time to buy MRNA stock, according to Wall Street analysts?
Out of 15 sell side analysts who research MRNA, the consensus analyst rating on Moderna is a Hold
It's important to keep in mind that analyst forecasts are not stock recommendations, nor are they financial advice.
Most Recent MRNA Analyst Upgrades/Downgrades
Tyler Van Buren, a top 40% analyst from TD Cowen maintains MRNA with a hold rating and raises their MRNA price target from $40.00 to $90.00, on Oct 21, 2026.
Geoff Meacham, a top 7% analyst from Citigroup downgrades MRNA to a strong sell rating and raises their MRNA price target from $60.00 to $80.00, on Sep 30, 2026.
Simon Baker, a bottom 18% analyst from Rothschild & Co downgrades MRNA to a strong sell rating and raises their MRNA price target from $40.00 to $81.00, on Sep 3, 2026.
John Eade, a top 9% analyst from Argus Research upgrades MRNA to a strong buy rating and announces their MRNA price target of $180.00, on Aug 28, 2026.
Argus Research's John Eade upgraded their rating on Moderna (NASDAQ: MRNA) from Hold to Strong Buy on 2026/08/28. The analyst also announced a $180 price target.
Moderna and Merck announced results from a phase III clinical trial of a personalized mRNA vaccine to reduce the risk of melanoma returning in a phase III clinical trial.
Upgrading the stock, Eade backgrounded that the company now has five products currently approved for human use.
One is one of the three approved COVID-19 vaccines in the U.S.
The second is a lower-dose COVID-19 vaccine
The third is a recently approved combination flu/COVID-19 vaccine.
The fourth is an mRNA vaccine for RSV.
The fifth is the first mRNA-based influenza vaccine approved in the U.S.
Alexandria Hammond, a top 28% analyst from Wolfe Research upgrades MRNA to a hold rating, on Aug 25, 2026.
You can dig deeper into what analysts are forecasting on the Moderna stock forecast page.
MRNA Momentum
SMA10
233.78
SMA20
225.68
SMA50
205.61
SMA100
146.94
SMA200
98.86
MACD
3.18
MACD Signal
9.88
MACD Histogram
-6.69
RSI
41.45
Stochastic %K
6.78
Stochastic %D
21.59
StochRSI %K
0
StochRSI %D
1.6
Is MRNA Making Money?
Last year, MRNA revenue was $2.53B. Over the past 5 year, MRNA's revenue has grown by -26.57% per year. This was slower than the Biotechnology industry average of 30.55%.
No, Moderna doesn't provide an income stream by paying out dividends.
Get opinions from other investors
One of the biggest reasons eToro is our highest-rated brokerage is because of its social trading community.
Click below to see what other traders have to say.
Step 5: Make your MRNA purchase
You have two primary types of orders:
Market order: A market order is an order to buy or sell a security at the best available price. Market orders are generally sufficient.
Limit order: A limit order lets you buy or sell a security at a specific price (or better). If you want to make sure you're buying or selling at an exact price, use a limit order.
Click the Open button and your broker will place your order.
If you want additional assistance buying stocks on eToro, click the how to video below:
As of Nov 18, 2026, it costs $196.79 to buy one share of Moderna stock.
Remember, eToro's fractional share buying allows you to buy partial shares of stocks and ETFs. Even if you only have $100, you can buy 0.508 shares of MRNA.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.